At a Glance
- CD34+ cell therapy platform company with an advanced clinical pipeline with two programs with cell therapy “breakthrough” designation
- Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio
- Multiple potential value creating events in the next 12 months based on development milestones across the pipeline
- Strong balance sheet; $33.7 million in cash (June 30, 2019) with no debt and cash runway projected through mid-2020
- Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience
Maximum 30 minute delay for quote.